AbbVie Inc. (ABBV)
3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever
Abbott Labs produces medications as just one of its revenue sources. AbbVie has shown a knack for expanding the markets of its drugs.
2 Incredibly Cheap Healthcare Stocks to Buy Now
Both of these stocks have something to offer income-seeking investors. AbbVie is moving on from the loss of patent exclusivity for the world's top-selling drug.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AbbVie Already Has The Next Humira
AbbVie delivered Y/Y growth in the second quarter despite Humira's decline, with Skyrizi and Rinvoq as key growth drivers, achieving 45% and 56% Y/Y growth, respectively. I expect Skyrizi to become a bigger product for AbbVie than Humira was at its peak in 2021. Skyrizi's robust efficacy and good safety in psoriasis, psoriatic arthritis, and inflammatory bowel diseases support its strong long-term growth prospects.
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
AbbVie is a Dividend King that has proven it can successfully navigate challenges. Lowe's Companies is a great stock to own over the long run because homes will always need to be fixed up.
3 Best Growth Stocks to Own for the Next 10 Years
During times of market volatility, it's always good for long-term investors to take a breath and zoom out. That doesn't mean getting out of the markets as fast as possible.
AbbVie: I'm Up 149% And Holding This Dividend Aristocrat Now
AbbVie is one of my biggest winners and a top 10 holding in my portfolio. The company's increasing contributions from Skyrizi and Rinvoq pushed net revenue higher in Q2. AbbVie maintains its A- credit rating from S&P on a stable outlook.
Prediction: Eli Lilly's Latest Move Will Threaten AbbVie Stock
Eli Lilly is exploring whether its newest hit drug could be used to treat psoriasis. AbbVie's newest hit drugs already treat psoriasis, among other conditions.
Why AbbVie Remains One Of My Favorite Dividend Growers
AbbVie has shown strong growth, especially in immunology and oncology, with Skyrizi and Rinvoq driving impressive sales and long-term growth potential. Despite Humira's patent loss, AbbVie has managed a "soft landing" and continues to innovate, particularly in neuroscience and oncology. The company offers a solid dividend with a 51% payout ratio and consistent growth, making it attractive for conservative investors seeking income and growth.
2 Stocks to Buy Now Before a Stock Market Crash
A recession is looming. Despite the S&P 500 nearing its all-time high, the yield curve inverted and the
3 Unstoppable Dividend Stocks to Buy Right Now
Abbott Laboratories is a Dividend King with a diverse business. Amgen offers a high dividend yield plus a track record of innovation.
Is Merck Stock A Better Pick Over AbbVie?
We believe that the pharmaceuticals giant Merck (NYSE: MRK) is currently a better pick over its peer, AbbVie stock. MRK stock trades at 14x forward earnings, versus 20x for ABBV.
